Utzeri E, Usai P. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(22): 3954-3963 [PMID: 28652650 DOI: 10.3748/wjg.v23.i22.3954]
Corresponding Author of This Article
Paolo Usai, Associate Professor, Department of Medical Sciences, University of Cagliari, Via Università, 40, 09124 Cagliari, Italy. usaip@medicina.unica.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 14, 2017; 23(22): 3954-3963 Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.3954
Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease
Erika Utzeri, Paolo Usai
Erika Utzeri, Paolo Usai, Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
Author contributions: Usai P substantially contributed to the conception and design of the review; Utzeri E contributed to the acquisition of data and drafting the article.
Conflict-of-interest statement: Utzeri E and Usai P declare no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Paolo Usai, Associate Professor, Department of Medical Sciences, University of Cagliari, Via Università, 40, 09124 Cagliari, Italy. usaip@medicina.unica.it
Telephone: +39-70-51096138 Fax: +39-70-51096138
Received: October 26, 2016 Peer-review started: October 28, 2016 First decision: December 19, 2016 Revised: January 19, 2017 Accepted: February 7, 2017 Article in press: February 7, 2017 Published online: June 14, 2017
Core Tip
Core tip: Among the gastro-intestinal effects, in non-steroidal anti-inflammatory drugs (NSAIDs) users, those of the lower tract seem to be rising. NSAIDs enteropathy is due to the enterohepatic recycling of drugs, resulting in a prolonged and repeated exposure of the intestinal mucosa to the compound and its metabolites, leading to so called topical effects. The impairment of the intestinal barrier represents the initial damage of NSAIDs enteropathy that leads to the translocation of bacteria and toxic substances of intestinal origin in the portal circulation, promoting an endotoxaemia. This condition, mostly in patients with risk factors for nonalcoholic fatty liver diseas, such as obesity and metabolic syndrome, might lead to liver inflammatory response that could promote the development of nonalcoholic steatohepatitis.
